Eli Lilly & Co
LLY- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000059478
In the last 90 days, Eli Lilly & Co insiders filed 0 open-market purchases and 3 sales; 4,644 institutions reported holding it in 13F filings for Q2 2026, worth $942.7B in total; 4 superinvestors hold it, including ARK Invest and Soros Fund Management.
Q1 2026 vs. Q4 2025
How the institutions holding Eli Lilly & Co changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 4,452 | 73 | 4,391 | +12 |
| Shares | 789.6M | 97.2M | 776.4M | +84.0M (+12.1%) |
| Value | $843.2B | $104.4B | $712.9B | −$25.8B (−3.5%) |
73 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (240)
Institutions that held Eli Lilly & Co at the end of Q1 2026 but not at the end of Q4 2025.
Showing the largest 100 of 240 by value.
Sold out (228)
Institutions that held Eli Lilly & Co at the end of Q4 2025 and filed for Q1 2026 without it.
Showing the largest 100 of 228 by value.
Not filed for Q1 2026 yet (73)
Institutions that held Eli Lilly & Co at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.